Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
COMPANY
From Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions, Joins BioTalk
Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL’s remarkable success in precision medicine, making this episode a must-listen.
Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth
The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements.
First Lady of Virginia visits AMPEL
Suzanne Youngkin shared the goals of the W+g initiative focused on wellbeing and workforce in Virginia during her March 30th visit to AMPEL BioSolutions, a women-owned business founded, headquartered and growing in Charlottesville. The focus of AMPEL's business is...
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.
Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
PLATFORM
Bloomberg’s “The Tape” Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer.
MI/AL for Diagnosis & Prognosis
Presentation by Amrie Grammer, Ph.D, COO/CSO, AMPEL BioSolutions at the Precision Medicine World Conference on June 28, 2022
PRODUCTS
AMPEL BioSolutions Developing Molecular Test to Predict Kidney Damage in Lupus Nephritis Patients
According to the company, the test identifies molecular markers in kidney biopsy samples of LN patients, which can help reveal patients’ disease stage. This information, in turn, could help those pharmaceutical companies who have more than 45 LN drugs in development enroll patients in clinical trials with greater precision, AMPEL said.
This New Blood Test For Fibromyalgia Could Identify Your Best Treatment Options
Different from the FM/a blood test used for diagnosis, this new blood test for Fibromyalgia may be the key to your treatment plan.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ORIGINAL ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ — AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO READ ARTICLE > AMPEL BioSolutions announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is irreversible and providing decision support for prophylactic...
New test to identify, treat kidney disease
CLICK TO READ ARTICLE & VIEW VIDEO > By Felicity Taylor CHARLOTTESVILLE, Va. (CBS19 NEWS) -- A local company says it has discovered a new way to identify and treat kidney disease. AMPEL BioSolutions is a precision medicine company that studies RNA and gene...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
PARTNERS
Reuters – Google Webinar Featuring AMPEL for Pharma Partnering
Reuters Events webinar with AMPEL, Google Cloud, Novartis, Asklepios and Pfizer to learn how data-driven innovation is reshaping clinical trials and paving the way towards faster drug discovery, more diverse patient enrolment and improved patient retention.
AMPEL’s AL/ML in Clinical Trial Design
Panel Presentation at the Precision Medical World Conference, June 29, 2022
Podcast on Lupus Diagnosis & Treatment
An Interview with Dr. Amrie Grammer on Dartmouth's "No Scrubs" Podcast